ES2843561T3 - Sales farmacéuticamente aceptables del ácido beta-guanidinopropionico con propiedades mejoradas y usos de las mismas - Google Patents

Sales farmacéuticamente aceptables del ácido beta-guanidinopropionico con propiedades mejoradas y usos de las mismas Download PDF

Info

Publication number
ES2843561T3
ES2843561T3 ES16840104T ES16840104T ES2843561T3 ES 2843561 T3 ES2843561 T3 ES 2843561T3 ES 16840104 T ES16840104 T ES 16840104T ES 16840104 T ES16840104 T ES 16840104T ES 2843561 T3 ES2843561 T3 ES 2843561T3
Authority
ES
Spain
Prior art keywords
salt
pharmaceutically acceptable
gpa
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16840104T
Other languages
English (en)
Spanish (es)
Inventor
Eduardo Martinez
Andreas Grill
Aniruddh Singh
Padmini Kavuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspirna Inc
Original Assignee
Rgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rgenix Inc filed Critical Rgenix Inc
Application granted granted Critical
Publication of ES2843561T3 publication Critical patent/ES2843561T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES16840104T 2015-08-25 2016-08-25 Sales farmacéuticamente aceptables del ácido beta-guanidinopropionico con propiedades mejoradas y usos de las mismas Active ES2843561T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562209624P 2015-08-25 2015-08-25
PCT/US2016/048643 WO2017035331A1 (en) 2015-08-25 2016-08-25 PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES2843561T3 true ES2843561T3 (es) 2021-07-19

Family

ID=58100994

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16840104T Active ES2843561T3 (es) 2015-08-25 2016-08-25 Sales farmacéuticamente aceptables del ácido beta-guanidinopropionico con propiedades mejoradas y usos de las mismas

Country Status (16)

Country Link
US (4) US20170056352A1 (cg-RX-API-DMAC7.html)
EP (1) EP3340973B1 (cg-RX-API-DMAC7.html)
JP (2) JP6880023B2 (cg-RX-API-DMAC7.html)
KR (1) KR102707964B1 (cg-RX-API-DMAC7.html)
CN (2) CN114057611A (cg-RX-API-DMAC7.html)
AU (1) AU2016311368B2 (cg-RX-API-DMAC7.html)
CA (1) CA2996520C (cg-RX-API-DMAC7.html)
DK (1) DK3340973T3 (cg-RX-API-DMAC7.html)
ES (1) ES2843561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210044T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053963T2 (cg-RX-API-DMAC7.html)
PL (1) PL3340973T3 (cg-RX-API-DMAC7.html)
PT (1) PT3340973T (cg-RX-API-DMAC7.html)
RS (1) RS61804B1 (cg-RX-API-DMAC7.html)
SI (1) SI3340973T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017035331A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168465A1 (en) 2014-04-30 2015-11-05 Rgenix, Inc. Inhibitors of creatine transport and uses thereof
US20190125745A1 (en) * 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018160178A1 (en) * 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
JP2023505687A (ja) 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
KR102615692B1 (ko) * 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물
CN119421865A (zh) * 2022-04-21 2025-02-11 默沙东有限责任公司 制备附聚的结晶中链脂肪酸钠盐的方法
KR102822799B1 (ko) 2022-11-09 2025-06-20 충남대학교산학협력단 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA101653A (en) 1906-08-30 1906-10-23 Herman Besser Mould
US3933797A (en) * 1972-02-22 1976-01-20 Pfizer Inc. 6-[α-(ω-QUANIDINOALKANOYLAMIDO)ACYLAMIDO]PENICILLANIC ACIDS
BE794886A (fr) 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
US3972872A (en) 1974-09-23 1976-08-03 Pfizer Inc. 6-[α-(ω-Guanidinoalkanoylamido)acylamido]penicillanic acids
EP0260118B1 (en) 1986-09-10 1991-12-04 Syntex (U.S.A.) Inc. Selective amidination of diamines
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
CA2028593C (en) * 1989-10-31 2007-08-21 Douglas R. Brandt Stabilized enzyme compositions
DE4334639A1 (de) 1993-10-11 1995-04-13 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung von TiN-Sinterkörpern und -Schichten
US5994577A (en) 1994-11-23 1999-11-30 Larsen; Scott D. Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
DE793646T1 (de) * 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
JP3745439B2 (ja) 1995-07-06 2006-02-15 花王株式会社 皮膚外用剤
TW453881B (en) 1995-10-16 2001-09-11 Kao Corp Cosmetic composition comprising amide derivatives
JPH09202710A (ja) * 1995-11-20 1997-08-05 Kao Corp しわ改善剤
JP2000511177A (ja) 1996-05-21 2000-08-29 ファルマシア・アンド・アップジョン・カンパニー インスリン非依存性糖尿病治療のためのアミノグアニジンカルボキシレート ラクタム類
JP4317599B2 (ja) 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
CN1305376A (zh) 1998-06-30 2001-07-25 武田药品工业株式会社 治疗糖尿病的药物组合物
EP1656945A1 (en) 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmaceutical composition comprising oligoarginine
ATE356629T1 (de) 1999-06-05 2007-04-15 Univ Leland Stanford Junior Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US20020082448A1 (en) 1999-11-08 2002-06-27 The Upjohn Company Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
US7335723B2 (en) 2001-08-08 2008-02-26 Merck & Co., Inc. Melanin-concentrating hormone antagonists
JP2005518346A (ja) 2001-11-07 2005-06-23 メディカル リサーチ カウンセル ドパミン作動性ニューロンの調節
EP1495046A2 (en) 2002-01-09 2005-01-12 Merck & Co., Inc. Selective melanin concentrating hormone type 1 receptor agonists
JP2005528424A (ja) 2002-06-04 2005-09-22 アビセナ グループ インコーポレイティッド 脳内エネルギー代謝を調節することによって認知機能障害を治療する方法
US20120245211A1 (en) 2002-06-04 2012-09-27 Children's Hospital Medical Center Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
GB0302882D0 (en) 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP4865251B2 (ja) 2005-05-09 2012-02-01 株式会社 資生堂 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物
WO2007014756A1 (de) 2005-08-02 2007-02-08 Alzchem Trostberg Gmbh Flüssig-formulierung auf basis einer guanidinoessigsäure- komponente
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
AU2007333105A1 (en) 2006-12-11 2008-06-19 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
BRPI0807157A2 (pt) 2007-02-08 2014-04-29 Kempharm Inc Pró-farmacos hidrófilos polares de anfetamina e outros estimulantes e processos para fabricação e uso dos mesmos
CN101848918A (zh) 2007-09-07 2010-09-29 吉奇亚公司 线粒体组合物及其用途
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
FR2940077B1 (fr) 2008-12-19 2012-07-20 Oreal Procede de coloration eclaircissante de matieres keratiniques mettant en oeuvre une composition anhydre colorante comprenant un agent alcalin et une composition oxydante.
BRPI0907287B1 (pt) 2008-12-19 2018-01-02 L'oréal "processo de clareamento ou de coloração das fibras queratínicas e dispositivo com vários comportamentos"
FR2940104B1 (fr) 2008-12-19 2011-08-19 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une composition contenant un agent alcalin
JP5866137B2 (ja) 2009-04-30 2016-02-17 ロレアル アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン化合物を含む組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置
WO2011031308A1 (en) 2009-09-09 2011-03-17 Cytokinetics, Incorporated Novel combinations
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
FR2954160B1 (fr) 2009-12-22 2012-03-30 Oreal Composition de coloration ou d'eclaircissement comprenant un corps gras et un polymere amphotere
JP5544024B2 (ja) 2009-12-31 2014-07-09 ケムファーム・インコーポレーテッド クエチアピンのアミノ酸結合体、その製造法及び使用法
DE102010012199A1 (de) 2010-03-19 2011-09-22 Fresenius Medical Care Deutschland Gmbh Molekular geprägte Polymere für die Eliminierung von Metaboliten
FR2958161B1 (fr) 2010-04-02 2012-04-27 Oreal Procede de traitement des cheveux mettant en oeuvre une emulsion directe comprenant un agent oxydant et une emulsion directe contenant un agent alcalin
EP3540059A1 (en) 2010-04-16 2019-09-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
WO2011133150A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
BR112012026768A2 (pt) 2010-04-21 2015-09-29 Signature Therapeutics Inc composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores.
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
CA2794864A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
US20130281410A1 (en) 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders
EP2399885A1 (en) 2010-06-22 2011-12-28 Ulrich Dietz Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification
WO2012024611A1 (en) 2010-08-20 2012-02-23 Natural Alternatives International, Inc. Methods of treating sarcopenia and frailty
WO2012047630A2 (en) 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US8765115B2 (en) 2010-12-01 2014-07-01 National Institute of Agrobiological Scienses Method of treatment of gastrointestinal disorders with IL-10
CA2827662C (en) 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
WO2012122412A2 (en) 2011-03-09 2012-09-13 Signature Therapeutics, Inc. Compositions for reducing risk of adverse events caused by drug-drug interactions
WO2012138214A1 (en) * 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102850242A (zh) * 2011-06-27 2013-01-02 天津天成制药有限公司 胍基丙酸硝酸盐的制备方法
US8427223B2 (en) 2011-07-19 2013-04-23 Lsi Corporation Voltage level translator circuit for reducing jitter
PL2736510T3 (pl) 2011-07-28 2017-07-31 Kempharm, Inc. Proleki metylofenidatu, procesy ich wytwarzania i stosowania
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
FR2983407B1 (fr) 2011-12-06 2014-01-03 Oreal Composition aqueuse riche en huile et son utilisation dans un procede de coloration d'oxydation ou de decoloration
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
PL2854764T3 (pl) 2012-06-05 2019-07-31 Neuroderm Ltd Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
AU2013337768B2 (en) * 2012-10-31 2015-07-02 The Rockefeller University Treatment and diagnosis of colon cancer
FR2997846B1 (fr) 2012-11-09 2023-10-20 Oreal Composition comprenant un derive dicarbonyle et un acide, le procede de lissage des fibres keratiniques a partir de cette composition
WO2014138492A1 (en) 2013-03-08 2014-09-12 Solan, LLC Methods for fabricating graphite-based structures and devices made therefrom
CN103288685B (zh) * 2013-07-03 2015-02-18 郭礼强 一种3-胍基丙酸的制备方法
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Also Published As

Publication number Publication date
EP3340973B1 (en) 2020-10-14
US9827217B2 (en) 2017-11-28
US20170056352A1 (en) 2017-03-02
US10512623B2 (en) 2019-12-24
CN114057611A (zh) 2022-02-18
HK1257822A1 (en) 2019-11-01
PT3340973T (pt) 2021-01-19
EP3340973A4 (en) 2019-04-03
JP2021121597A (ja) 2021-08-26
WO2017035331A1 (en) 2017-03-02
RS61804B1 (sr) 2021-06-30
JP2018531280A (ja) 2018-10-25
US20200138759A1 (en) 2020-05-07
AU2016311368B2 (en) 2020-10-08
JP7134294B2 (ja) 2022-09-09
CN108472269A (zh) 2018-08-31
SI3340973T1 (sl) 2021-07-30
CA2996520A1 (en) 2017-03-02
US20180243248A1 (en) 2018-08-30
KR20180059446A (ko) 2018-06-04
CN108472269B (zh) 2021-11-02
PL3340973T3 (pl) 2021-06-14
HUE053963T2 (hu) 2021-07-28
EP3340973A1 (en) 2018-07-04
DK3340973T3 (da) 2021-01-11
AU2016311368A1 (en) 2018-03-29
HRP20210044T1 (hr) 2021-04-30
US20170056353A1 (en) 2017-03-02
CA2996520C (en) 2024-11-19
KR102707964B1 (ko) 2024-09-20
JP6880023B2 (ja) 2021-06-02

Similar Documents

Publication Publication Date Title
ES2843561T3 (es) Sales farmacéuticamente aceptables del ácido beta-guanidinopropionico con propiedades mejoradas y usos de las mismas
ES3034158T3 (en) Novel salt of terphenyl compound
ES2981043T3 (es) Procedimiento para fabricar tosilato de glicopirrolato treo
JP2018531280A6 (ja) 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用
ES3022913T3 (en) Solid forms of a cdk4 inhibitor
ES2402791T3 (es) Forma cristalina de la sal diclorhidrato de ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
ES2956943T3 (es) Forma cristalina de AZD9291 deuterado, procedimiento de preparación para la misma y uso de la misma
CN108026075B (zh) 普那布林组合物
AU2017254687A1 (en) Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
ES2682965T3 (es) Formas de rifaximina y sus usos
ES2694297T3 (es) Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético
EA034571B1 (ru) Пролекарства аналогов глутамина
ES2889476T3 (es) Composiciones y procedimientos relacionados con agonistas 5-HT1F de piridoilpiperidina
EP4108666A1 (en) Multi-target tyrosine kinase inhibitor
ES2908349T3 (es) Sal de derivado de quinazolina o cristal de la misma, y método para producir sal de derivado de quinazolina o cristal de la misma
ES2632548T3 (es) Formas de estado sólido de los inhibidores de la quinasa macrocíclica
ES2844425T3 (es) Forma polimórfica cristalina de 3-hidroxi-4,5-bis-benciloxi-6-benciloximetil-2-fenil-2-oxo-2lambda5-[1,2]oxafosfinano
ES2982346T3 (es) Sales metálicas y usos de las mismas
ES2893424T3 (es) Sal de derivado de cefalosporina, su forma sólida cristalina y método para producirla
WO2021057796A1 (zh) 取代的稠合三环衍生物及其组合物及用途
EP4512808A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
ES2845639T3 (es) Forma cristalina de 6-[(4R)-4-metil-1,2-dióxido-1,2,6-tiadiazinan-2-il]isoquinolin-1-carbonitrilo
JP5651271B2 (ja) デニブリン二塩酸塩
HK40062831A (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF β-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
CN119684195A (zh) 一种以金刚烷为疏水基团修饰的prmt1蛋白降解剂及其应用